Health ecosystem players in China are adopting DeepSek’s generative AI models, a competitor to OpenAI. Notable integrations include Akso Health Group’s diagnostic systems, ClouDr’s hospital platforms, and Waterdrop’s smart insurance solutions. DeepSek’s cost-effective models have gained global traction but faced bans in countries like Australia and the U.S. over national security concerns.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
